Q2 费用率18.9%，同比提升8 个pct，预计一是产线建设导致费用化支出增加；二是新品推广前期人员 增加较多。最终Q2 归属净利润小幅盈利，净利率同比下滑8.8pct。 收并购推进，向上游扩张。公司与上海妙翔等签订股权转让协议，公司拟合计受让标的公司苏州创扬新 材料科技股份有限公司3405 万股股份，转让价款合计为8400 万元，转让完成后公司持股标的公司30% 股份，标的公司主营药用塑料组合盖等，并承诺2025-2027年归属净利润不低于2500 万元、3500 万元、 4500 万元。 从管制到模制，从制瓶到拉管。公司最早从事低硼硅药用玻璃销售，后逐步切入中硼硅领域，并在管制 瓶领域处领先地位。展望未来，公司优势产品中硼硅管制瓶将继续扩张。此外产品的横纵向扩张也将加 速，一方面中硼硅模制瓶有望放量，另一方面开始切入管制瓶上游拉管生产。公司2024 年4 月底中硼硅 模制瓶的注射剂瓶通过转A、10 月输液瓶通过转A，后续随着其他客户的备案完成公司模制瓶有望进入 放量周期。 事件描述 公司上半年实现收入5.0 亿，同比下滑11.1%；归属净利润0.4 亿 ，同比下滑20.1%。折合Q2 收入2.23 亿， ...

丨证券研究报告丨 公司研究丨点评报告丨力诺药包（301188.SZ） [Table_Title] 药包承压，耐热盈利改善 报告要点 分析师及联系人 [Table_Author] 范超 李浩 SAC：S0490513080001 SAC：S0490520080026 SFC：BQK473 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com [Table_Summary] 公司上半年实现收入 5.0 亿，同比下滑 11.1%；归属净利润 0.4 亿 ，同比下滑 20.1%。折合 Q2 收入 2.23 亿，同比下滑 24.2%；归属净利润 44 万元，同比下滑 98.3%。 [Table_Title2] 药包承压，耐热盈利改善 [Table_Summary2] 事件描述 公司上半年实现收入 5.0 亿，同比下滑 11.1%；归属净利润 0.4 亿 ，同比下滑 20.1%。折合 Q2 收入 2.23 亿，同比下滑 24.2%；归属净利润 44 万元，同比下滑 98.3%。 事件评论 风险提示 1、新产品扩张不及预期； 1 力诺药包（301188.SZ） cjzqdt11111 ...

Core Insights - The molded bottle market holds a significant share in the borosilicate glass segment, accounting for approximately 44% of the market in 2024 [1] - The market for borosilicate ampoules is projected to grow from 600 million yuan in 2018 to 2.5 billion yuan in 2024 [2] - The market for neutral borosilicate molded bottles is expected to increase from 900 million yuan in 2018 to 3.8 billion yuan in 2024 [5] - The market for neutral borosilicate tubular bottles (excluding ampoules) is anticipated to grow from 600 million yuan in 2018 to 2.3 billion yuan in 2024 [6] - The strategic positioning of the borosilicate glass market indicates that neutral borosilicate molded bottles and ampoules are "star markets" with high growth potential and strong competitive positions [8] Market Analysis - The molded bottle segment is the largest within the borosilicate glass market, highlighting its importance in the pharmaceutical packaging industry [1] - The growth trajectory of the borosilicate ampoule market reflects increasing demand, with a substantial rise in market size over the years [2] - The neutral borosilicate molded bottle market is also experiencing significant growth, indicating a robust demand for this type of packaging [5] - The neutral borosilicate tubular bottle market, while growing, is currently positioned with moderate demand potential and competition [6] - The analysis using the Boston Matrix framework suggests that the borosilicate glass industry has promising segments that could attract investment and development [8]

Industry Overview - Borosilicate glass is a specialized product with excellent thermal shock resistance and water resistance, widely used for packaging pharmaceuticals such as injections, blood products, and vaccines [1][2] - The market for borosilicate glass in China is projected to reach approximately 8.6 billion yuan by 2024, with a penetration rate of about 25% [20] Industry Chain Analysis - The upstream materials for borosilicate glass production include quartz sand, boron sand, and other raw materials, while the downstream applications primarily involve medical institutions and pharmaceutical logistics [2][6] - Key players in the upstream supply include companies like Quartz Co. and Corning, while major manufacturers in the midstream include domestic firms like Shandong Pharmaceutical Glass and Zhengchuan Co. [6] Development History - The development of borosilicate glass in China began in the 1950s, with significant advancements occurring after 2004 when Shandong Pharmaceutical Glass introduced the first domestic production technology [9] - The industry has seen a shift towards domestic production capabilities, reducing reliance on imports and addressing long-standing supply chain issues [9] Policy Background - Recent policies emphasize the importance of quality in pharmaceutical packaging materials, with the National Medical Products Administration reinforcing standards for injection packaging [11][12] - The "14th Five-Year Plan" for the pharmaceutical industry aims to enhance the standardization and quality of pharmaceutical excipients and packaging materials [11][12] Market Structure - The market for borosilicate glass is segmented, with molded bottles accounting for 44% of the market share in 2024, while ampoules and tubular bottles hold similar shares [21] - The competitive landscape features a tiered structure, with leading companies like Shandong Pharmaceutical Glass and Zhengchuan Co. dominating the market, while other firms lag behind in market share and technological advancement [26][29] Future Outlook - The market for borosilicate glass is expected to grow significantly, potentially reaching 21.5 billion yuan by 2030, driven by increased demand and ongoing policy support [32] - The industry is anticipated to experience a trend towards technological innovation and increased competition, with domestic companies improving product quality and reducing costs [35]

Core Viewpoint - The company experienced a decline in revenue but improved net profit and gross margin due to a shift in product mix towards higher-margin borosilicate glass products [2][3]. Revenue and Profit Summary - In 2024, the company achieved revenue of 800 million yuan, a year-on-year decrease of 11.1% [2]. - The net profit attributable to shareholders was 50 million yuan, an increase of 32.2% year-on-year [2]. - The non-recurring net profit attributable to shareholders was also 50 million yuan, reflecting a year-on-year increase of 65.1% [2]. - The gross margin improved to 20.7%, up 4.7 percentage points from the previous year, driven by an increase in the proportion of high-margin borosilicate glass products [2]. Product Segment Performance - Borosilicate glass bottles generated revenue of 420 million yuan, down 0.8% year-on-year, with a gross margin of 22.8%, up 8.3 percentage points [2]. - Sodium-calcium glass bottles had revenue of 300 million yuan, a decrease of 16.2%, with a gross margin of 17.5%, up 2.0 percentage points [2]. - Bottle caps generated revenue of 70 million yuan, down 35.7%, with a gross margin of 18.5%, down 1.1 percentage points [2]. Research and Development Investment - The company increased R&D investment to 60 million yuan, a rise of 22.6% year-on-year [3]. - The company completed the full product layout in the pharmaceutical glass bottle sector, achieving large-scale production capabilities for various borosilicate products [3]. Financial Management and Dividends - The company announced a cash dividend plan for 2024, proposing a distribution of 2.46 yuan per 10 shares, which represents 98.3% of the net profit attributable to shareholders [3]. - The sales, management, R&D, and financial expense ratios were 1.8%, 5.4%, 2.5%, and 1.8%, respectively, with variations in each category compared to the previous year [3]. Profit Forecast and Investment Suggestion - The company is expected to benefit from industry growth and the gradual promotion of new products, with projected net profits of 64 million yuan, 74 million yuan, and 85 million yuan for 2025-2027, corresponding to PE ratios of 40, 35, and 30 [4].